Melanoma Treatment Denied by Insurance: How to Appeal

Melanoma is the most lethal form of skin cancer, yet it has also been one of the greatest success stories of modern oncology — with checkpoint immunotherapy and targeted BRAF/MEK inhibitors dramatically improving survival in advanced disease. Despite clear clinical evidence and FDA approvals, insurance denials for melanoma treatment remain common. Whether you've been denied ipilimumab, nivolumab, pembrolizumab, a BRAF inhibitor combination, Mohs micrographic surgery, or sentinel lymph node biopsy, you have the right to appeal and a strong basis to win.

Why Melanoma Treatment Gets Denied

Checkpoint inhibitors (Keytruda, Opdivo, Yervoy)

Pembrolizumab (Keytruda) and nivolumab (Opdivo) are FDA-approved for unresectable or metastatic melanoma. Ipilimumab (Yervoy) plus nivolumab combination therapy is approved for advanced melanoma and shows durable responses. Insurers deny these therapies by:

• Requiring Prior Authorization Denied: How to Appeal" class="auto-link">prior authorization with documentation of unresectability or metastatic staging
• Demanding PD-L1 testing even when the melanoma approval is not PD-L1 restricted
• Applying step therapy requiring single-agent IO before approving combination therapy
• Denying adjuvant pembrolizumab or nivolumab after resection of stage IIB-IV melanoma, despite FDA approval

BRAF and MEK inhibitors (Tafinlar, Mekinist, Zelboraf, Cotellic)

Approximately 40-50% of melanomas carry BRAF V600 mutations, making them eligible for targeted therapy with BRAF inhibitors (dabrafenib, vemurafenib) and MEK inhibitors (trametinib, cobimetinib) in combination. Denial reasons include:

• Absence of BRAF testing documentation — insurers may also deny the BRAF test itself
• Requirement to use vemurafenib (older generation) before approving dabrafenib + trametinib combination
• Denial of combination therapy in favor of monotherapy, citing cost

Mohs micrographic surgery

Mohs surgery is the standard of care for melanoma in situ and selected invasive melanomas in high-risk locations (head, neck, hands, feet, genitalia), as well as for most non-melanoma skin cancers. Insurers deny Mohs by:

• Classifying it as "cosmetic" — this is incorrect; Mohs is a cancer removal procedure
• Requiring it be performed in a hospital rather than a dermatologic surgery office
• Denying the number of stages as "excessive" without reviewing the pathology

Sentinel lymph node biopsy (SLNB)

SLNB is standard staging for melanomas ≥ 0.8 mm thick (T1b and above) per NCCN guidelines. It provides critical prognostic information and guides adjuvant therapy decisions. Insurers may deny SLNB as "not medically necessary" despite its role in staging, or may deny the associated lymphoscintigraphy mapping.

Adjuvant Therapy Denials

Following surgical resection, patients with stage IIB-IV melanoma may be eligible for adjuvant pembrolizumab, nivolumab, or dabrafenib + trametinib. These adjuvant approvals significantly reduce recurrence risk. Insurers sometimes deny adjuvant immunotherapy because the patient "does not currently have active disease," failing to understand that adjuvant treatment is specifically indicated in the post-resection setting.

Your Legal Rights

ACA protections: Cancer treatment is an essential health benefit. No annual or lifetime limits.

Medical necessity standard: When NCCN Category 1 evidence supports the recommended treatment and FDA approval exists, "not medically necessary" denials are almost always challengeable.

External Independent Review: Complete Guide" class="auto-link">External review rights: All patients have the right to independent external review. For melanoma, the external reviewer must be a board-certified oncologist or dermatologist familiar with current treatment protocols.

State step therapy laws: Multiple states protect patients from step therapy requirements in oncology. If your state has such a law, monotherapy-before-combination requirements may be legally overridable.

How to Build Your Appeal

Your appeal package should include:

1. Pathology report with Breslow thickness, Clark level, ulceration status, mitotic rate, and any BRAF mutation results
2. Staging documentation — radiology reports, SLNB results if applicable
3. NCCN Melanoma Guidelines for your specific stage and mutation status (available at NCCN.org)
4. Letter of medical necessity from your dermatologic oncologist or medical oncologist
5. FDA approval documentation for the specific agent and indication
6. Clinical trial data if applicable (KEYNOTE-716 for adjuvant pembro in stage IIB/IIC, CheckMate 238 for adjuvant nivolumab)

Directly address the insurer's stated reason for denial. Denials citing "investigational" for FDA-approved adjuvant immunotherapy are particularly vulnerable to reversal.

Fight Back With ClaimBack

ClaimBack helps melanoma patients navigate the appeal process with confidence. Our platform helps you assemble the clinical documentation that matters and frame your case in language insurers and external reviewers take seriously.

Start your appeal at ClaimBack

An insurance denial for melanoma treatment is not the end of the road. Most well-documented appeals succeed — and time matters in melanoma care.

Related Reading

• How to Write an Insurance Appeal Letter
• What Is Medical Necessity?
• Internal vs. External Insurance Appeals